Price at 130 Euro, Dupixent and Pipeline in Focus of Investing.com

Investing.com – The US-Bank Citi that converted the price of Sanofi (EPA:) from 125 to 130 euros and made the purchase at “Buy” prices. Analyst Peter Verdult has been working on a monthly study, with European Pharmacovigilance (with Ausnahme von Novo Nordisk (NYSE:)) between 2024 and 2029, with a minimum of 5 to 8% of results eines overlying CAGR of 8 to 15% with a Bewertungsabschlag of 20% was traded.

The analyses of the analyses, which show the longevity of Dupixent and the pipeline observations that provide forecasts for grippe impact material, are an attractive risk-opportunity relationship. The current outlook in the probable scenario is 185 euros, in the pessimistic scenario 87 euros. Sanofi’s peak allocation forecasts for the 12 most important pipeline products will be 30 and 60 billion euros, while Citi in its basic and sustainable scenarios will go for 15 to 20 billion euros, compared to the consensus of 10 billion euros.

The positive results of tolebrutinib, with a Citi forecast of 2.6 billion euros (kings: 1.4 billion euros), are a lot of money for Sanofi’s strong F&E products. All potential drugs and the profitability of the Phase III program for itepekimab (COPD), amlitelimab (AD/asthma) and frexalimab (MS/T1DM) can be explored on the market.

If the potential of the Dupixent franchise materializes, together with the peasant losses of the Amvuttra, which were estimated at 1 to 3 billion euros, the Verdult would be unreliable. Citi’s current forecast is 16 to 36% on sales growth, EBIT and earnings through 2030.

In own pocket: Do you want to know what investors’ portfolio results are? InvestingPro gives you access to the strategies and portfolios of top investors. There are always more than 100 actions performed, which are based on AI analyses. Curious? Click here for more information.